The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity

被引:46
作者
Brix, J. M. [1 ]
Hoellerl, F. [1 ]
Kopp, H-P [1 ]
Schernthaner, G. H. [2 ]
Schernthaner, G. [1 ]
机构
[1] Rudolfstiftung Hosp, Dept Med 1, A-1030 Vienna, Austria
[2] Med Univ Vienna, Div Angiol, Dept Med 2, Vienna, Austria
关键词
morbid obesity; sRAGE; insulin resistance; prospective; DECREASED PLASMA-LEVELS; END-PRODUCTS; INSULIN-RESISTANCE; CANCER INCIDENCE; SERUM-LEVELS; DISEASE; RAGE; ATHEROSCLEROSIS; INFLAMMATION; ASSOCIATION;
D O I
10.1038/ijo.2012.107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: The increased cardiovascular (CV) disease risk in patients with morbid obesity (MO) cannot be fully explained by traditional CV risk factors. Activation of the receptor of Advanced Glycation Endproducts (RAGE) leads to inflammation via the NF kappa beta (nuclear factor kappa beta) pathway. The soluble form of RAGE (sRAGE), which is present in plasma, can bind to ligands of RAGE and avoids interaction of RAGE with proinflammatory ligands. We investigated sRAGE levels in patients with MO and compared them with healthy lean controls (CO), before and after bariatric surgery. DESIGN: We conducted a cross-sectional study and a 24-month longitudinal study. SUBJECTS: We included 85 patients (mean age: 41 +/- 12 years; mean body mass index (BMI): 45.4 +/- 7.9 kg m(-2)) with MO in comparison with 40 CO (mean age: 42 +/- 13 years; mean BMI: 26.0 +/- 5.5 kg m(-2)). All patients were investigated before and 2 years after bariatric surgery. Apart from weight and CV risk markers (blood pressure, lipids), a glucose tolerance test (75 g), renal and inflammation parameters were assessed. sRAGE levels were assessed by a commercial ELISA. To investigate the associations of the observed reductions of values, delta (Delta) of parameters were calculated. RESULTS: Patients with MO had significant lower sRAGE levels than CO: 1010 +/- 514 vs 1501 +/- 674 pg ml(-1); P<0.001. In the longitudinal study, sRAGE levels increased significantly after bariatric surgery from 1010 +/- 514 to 1261 +/- 710 pg ml(-1); P = 0.008. In the correlation analysis, Delta sRAGE levels were associated with Delta 1-h and Delta 2-h postprandial glucose, Delta fasting insulin, Delta 2-h postprandial insulin, Delta HOMA (homeostatic model assessment)-insulin resistance (Delta HOMA-IR), Delta gamma-glutamyl transferase and Delta triglycerides. In a multivariate model, Delta 1-h and Delta 2-h postprandial glucose, Delta 2-h postprandial insulin and Delta HOMA-IR predicted Delta sRAGE. CONCLUSION: Patients with MO have significantly lower sRAGE levels compared with non-obese CO, but sRAGE levels increase significantly after weight loss induced by bariatric surgery. As high sRAGE levels inhibit the activation of inflammatory pathways, our results might help understand the beneficial effects of bariatric surgery regarding CV morbidity and mortality. International Journal of Obesity (2012) 36, 1412-1417; doi:10.1038/ijo.2012.107; published online 17 July 2012
引用
收藏
页码:1412 / 1417
页数:6
相关论文
共 41 条
[1]   Cancer Incidence and Mortality After Gastric Bypass Surgery [J].
Adams, Ted D. ;
Stroup, Antoinette M. ;
Gress, Richard E. ;
Adams, Kenneth F. ;
Calle, Eugenia E. ;
Smith, Sherman C. ;
Halverson, R. Chad ;
Simper, Steven C. ;
Hopkins, Paul N. ;
Hunt, Steven C. .
OBESITY, 2009, 17 (04) :796-802
[2]   Advanced glycation end products activate endothelium through signal-transduction receptor RAGE - A mechanism for amplification of inflammatory responses [J].
Basta, G ;
Lazzerini, G ;
Massaro, M ;
Simoncini, T ;
Tanganelli, P ;
Fu, CF ;
Kislinger, T ;
Stern, DM ;
Schmidt, AM ;
De Caterina, R .
CIRCULATION, 2002, 105 (07) :816-822
[3]   Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes [J].
Basta, G ;
Schmidt, AM ;
De Caterina, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :582-592
[4]   Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein [J].
Basta, Giuseppina ;
Sironi, Anna Maria ;
Lazzerini, Guido ;
Del Turco, Serena ;
Buzzigoli, Emma ;
Casolaro, Arturo ;
Natali, Andrea ;
Ferrannini, Ele ;
Gastaldelli, Amalia .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) :4628-4634
[5]   Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease [J].
Basta, Giuseppina ;
Leonardis, Daniela ;
Mallamaci, Francesca ;
Cutrupi, Sebastiano ;
Pizzini, Patrizia ;
Gaetano, Lorena ;
Tripepi, Rocco ;
Tripepi, Giovanni ;
De Caterina, Raffaele ;
Zoccali, Carmine .
KIDNEY INTERNATIONAL, 2010, 77 (03) :225-231
[6]   Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications [J].
Bierhaus, A. ;
Nawroth, P. P. .
DIABETOLOGIA, 2009, 52 (11) :2251-2263
[7]   RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease [J].
Bucciarelli, LG ;
Wendt, T ;
Rong, L ;
Lalla, E ;
Hofmann, MA ;
Goova, MT ;
Taguchi, A ;
Yan, SF ;
Yan, SD ;
Stern, DM ;
Schmidt, AM .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (07) :1117-1128
[8]   RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice [J].
Bucciarelli, LG ;
Wendt, T ;
Qu, W ;
Lu, Y ;
Lalla, E ;
Rong, LL ;
Goova, MT ;
Moser, B ;
Kislinger, T ;
Lee, DC ;
Kashyap, Y ;
Stern, DM ;
Schmidt, AM .
CIRCULATION, 2002, 106 (22) :2827-2835
[9]   Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients [J].
Chiang, Kuang-Hsing ;
Huang, Po-Hsun ;
Huang, Shao-Sung ;
Wu, Tao-Cheng ;
Chen, Jaw-Wen ;
Lin, Shing-Jong .
CORONARY ARTERY DISEASE, 2009, 20 (04) :267-273
[10]   Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes An Analysis From the CARDS Trial [J].
Colhoun, Helen M. ;
Betteridge, D. John ;
Durrington, Paul ;
Hitman, Graham ;
Neil, Andrew ;
Livingstone, Shona ;
Charlton-Menys, Valentine ;
Bao, Weihang ;
DeMicco, David A. ;
Preston, Gregory M. ;
Deshmukh, Harshal ;
Tan, Kathryn ;
Fuller, John H. .
DIABETES, 2011, 60 (09) :2379-2385